Sign in
CompletedPhase 2

Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury

Key facts

Who runs it
Medical College of Wisconsin
Where
Milwaukee, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
11 people enrolled
Started
1 Feb 2025
Ended
30 Jun 2026
Type of study
Interventional
Treatments tested
  • 4.5mg daily dose of naltrexone
Record updated
2 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Presence of a traumatic cervical or thoracic spinal cord injury
  • Age ≥18
  • >6 months from time of injury
  • Central neuropathic pain related to SCI, based on evaluation of a Physical Medicine \& Rehabilitation Physician
  • DN4 questionnaire ≥ 4
  • English speaking

Who cannot take part

  • Adjustment in pain medications within the previous month
  • Current treatment with naltrexone or other opioid antagonist
  • Scheduled elective surgery during the duration of the study
  • Allergy to naltrexone
  • Chronic opioid treatment
  • Central neuropathic pain attributed to other etiology
  • Neuropathic pain attributed to the peripheral nervous system
  • PHQ9 ≥15 indicating moderately severe or severe depressive symptoms
  • Documented traumatic brain injury that would affect study participation, in the opinion of the investigator
  • Pregnant or breastfeeding
  • Illicit substance use per Wisconsin law

Where in United States

  • Medical College of WisconsinMilwaukee, United States

About the trial

What the trial wants to find out

The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spinal cord injury.

Read full original descriptionShow less

Hypothesis 1: LDN will decrease the severity of CNP in adult patients with SCI as measured by the Neuropathic Pain Scale (NPS) Hypothesis 2: LDN will improve quality of life of patients with SCI as measured by various validated clinical tools

There is no comparison group. This study is being completed to give investigators more information for how to best run a larger clinical trial.

Participants will be asked to take an oral dose of 4.5mg of naltrexone, daily, for 12 weeks.

The group in the trial

  • Low Dose NaltrexoneTreatment being tested

    Daily dose of 4.5mg of naltrexone

    Treatment: 4.5mg daily dose of naltrexone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Low Dose Naltrexone in the Treatment of Central Neuropathic Pain After Traumatic Spinal Cord Injury: A Pilot Study
Record updated
2 November 2026